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S U M M A R Y
Background: Helicobacter pylori infection is associated with gastritis and in some cases with gastric and
duodenal ulcers, and even adenocarcinoma. Antibiotic therapy has signiﬁcant limitations, such as the
high cost and the emergence of antibiotic-resistant strains, generating the need for new treatments. The
administration of antibody against H. pylori is a new effective therapeutic strategy. In this study, we
successfully developed a single-variable domain of heavy chain antibody against recombinant UreC.
Methods: A VHH phagemid library was constructed from immune camel heavy chain antibodies. The
nanobodies were displayed on M13 phage. Library selection was performed against UreC recombinant
protein. A speciﬁc single-variable domain of heavy chain antibody against UreC was screened in ﬁve
rounds of panning. The nanobody with the highest score in the phage ELISA was selected for soluble
expression. The nanobody was puriﬁed with a nickel–nitrilotriacetic acid (Ni–NTA) column and
conﬁrmed with sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blotting. Afﬁnity, speciﬁcity, and urease inhibitory properties of the nanobody were assayed.
Results: Here we showed the isolation and puriﬁcation of a speciﬁc nanobody with high afﬁnity against
UreC recombinant protein that can inhibit urease activity.
Conclusions: The isolated UreC nanobody can speciﬁcally detect and bind to UreC and inhibit urease
activity. This nanobody could be a novel class of treatment measure against H. pylori infection.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Helicobacter pylori is considered a major health threat. It is
estimated that almost half of the world’s population is infected
with this bacterium.1,2H. pylori causes gastritis in most people, and
in some cases can further induce more severe diseases such as
gastric and duodenal ulcers, and even gastric adenocarcinoma.3–5
The relevance of H. pylori infection to other disorders such as
cardiovascular, neurologic, ocular, and dermatological diseases has
recently been reported.6 Treatment of H. pylori infection usually
consists of antibiotics along with a proton pump inhibitor.7–9 The
emergence of antibiotic resistance,8,10 the high cost of the
currently available treatment measures, and the increase in the
number of reported relapses11 highlight the need for new
alternative therapeutic approaches.
UreC is one of the urease enzyme subunits showing great
potential in vaccine production. UreC is an antigenic protein that* Corresponding author.
E-mail addresses: slmousavi@shahed.ac.ir, mlatifm@yahoo.com (S.L.M. Gargari).
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http://dx.doi.org/10.1016/j.ijid.2013.02.015can stimulate a speciﬁc and innate response and contains an
enzyme active site.12 Urease was found in all clinical isolates and
was highly conserved among different strains.13 Furthermore,
antibodies against UreC were found in all patients suffering from
stomach ulcer and H. pylori infections.14 Based on our previous
research,15 UreC-speciﬁc antibodies can neutralize H. pylori urease
enzyme and reduce bacterial colonization in an in vitro environ-
ment. Antibodies, unlike antibiotics, can recognize certain antigens
on the microorganism and neutralize virulence factors that enable
the host immune system to interact with the microorganism, and
furthermore prevent relapses.16 Antibodies can bind to a wide
spectrum of antigens with versatile mechanisms and be useful in
the treatment of cancer, autoimmune, inﬂammatory, and infec-
tious diseases.17,18 However, classic antibodies have functional
limitations including interaction with the patient immune system
and inadequate pharmacokinetics or tissue accessibility.19,20
Heavy chain antibodies (HCAbs) – antibodies lacking the light
chain and CH1 domain – were discovered in the serum of camelids
in the early 1990s.21 These antibodies have a single variable
domain referred to as VHH, sdAb, or nanobody. Nanobodies have
better tissue penetration and effective pharmacodynamics withses. Published by Elsevier Ltd. All rights reserved.
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therapeutic value of nanobodies over conventional antibodies is due
to their small size (2.5 nm in diameter and nearly 4 nm high),24 high
stability at extreme temperatures and pH,23,25 physical stability,
capability of refolding,26and binding to unique epitopes inaccessible
to conventional antibodies.27 Recently, antibody administration
against urease enzyme for the treatment of H. pylori infection has
been studied as a new effective therapeutic strategy.28–32 Nano-
bodies have also been utilized for the treatment of several intestinal
infections such as retroviral intestinal infections.33 In this study was
aimed to produce a nanobody against the recombinant UreC subunit
of urease enzyme of H. pylori.
2. Materials and methods
2.1. Preparation of antigen
The pET28a vector carrying the UreC gene used in this study was
from our earlier work.15 The expression and puriﬁcation of
recombinant UreC protein was carried out as described previously.15
2.2. Immunization of Camelus dromedaries
The puriﬁed protein concentration was estimated by the
Bradford method.34 After collection of normal serum from a
non-immune camel, the dromedary was subcutaneously injected
with 1, 1.5, 2, 2.5, and 3 mg UreC at 2-week intervals. Freund’s
complete adjuvant (Razi Institute, Iran) was used for the ﬁrst
injection, followed by injection of the protein mixed with an equal
volume of Freund’s incomplete adjuvant for the booster doses.
Serum was taken 1 week after each booster injection for
measurement of the produced antibody level.
2.3. ELISA
A 96-well microplate (JET BIO FIL, Canada) was coated with
10 mg/ml of puriﬁed UreC recombinant protein per well and
incubated at 4 8C overnight. After washing with phosphate
buffered saline (PBS)–T (PBS 0.05% Tween-20), the wells were
blocked with 150 ml of 5% skim milk in PBS-T and incubated for 1 h
at 37 8C. One hundred microliters of serum at different dilutions
was added and incubated for 1 h at 37 8C. One hundred microliters
of a 1/16 000 dilution of rabbit anti-camel antibody in PBS-T was
added to each well and the microplate was incubated for 1 h at
37 8C. One hundred microliters of horseradish peroxidase (HRP)-
conjugated mouse anti-rabbit antibody (Abcam, UK) was added to
the wells at a ﬁnal concentration of 1/5000 and incubation was
performed at 37 8C for 1 h. One hundred microliters of tetra-
methylbenzidine (TMB) (Bangalore GeNei, India) was used as
substrate buffer. The reaction was incubated at 37 8C for 15 min
and was then stopped with 100 ml/well of 3 N H2SO4 and the
optical density (OD) was measured at 450 nm (OD450). Wells were
washed with 200 ml of PBS-T after each step.
2.4. VHH ampliﬁcation and library construction
After conﬁrming immunization, camel blood was taken in an
ethylenediaminetetraacetic acid (EDTA) coated tube, and peripheral
blood mononuclear lymphocytes (PBMCs) were isolated using a
Ficoll gradient. Total RNA was extracted from isolated lymphocytes
with the High Pure RNA Isolation Kit (Roche, USA). cDNA was
generated with a RevertAid First Strand cDNA Synthesis Kit
(Fermentase, Germany) using Oligo dT primer. A nested PCR was
used for VHH ampliﬁcation. In the ﬁrst PCR, fragments between
framework 1 and CH2 regions were ampliﬁed with two sets of
speciﬁc primers: CALL001: 50-GTC CTG GCT CTC TTC TAC AAG G-30;CALL002: 50-GGT ACG TGC TGT TGA ACT GTT CC-30; VHBACKA6: 50-
GAT GTG CAG CTG CAG GCG TCT GG(A/G) GGA GG-30; and
CH2FORTA4: 50-CGC CAT CAA GGT ACC AGT TGA-30.23,35–37
Fragments driven from heavy chain antibody (600 and 700 bp)
were puriﬁed from agarose gel with a Bioneer AccuPrep Gel
Puriﬁcation Kit and were then used as templates for the second PCR.
VHH was ampliﬁed using a speciﬁc degenerated VHH F primer: 50-
CTGGCCCAGGCGGCCGAGGTGCAGCTG(C/G)(A/T)G(C/G)A(G/T)TC
(G/T)G-30; and VHH R primer: 50-ACTGGCCGGCCTGGCCTGAGGA-
GACGGTGATGACC(A/T)GGGTC-30. These primers attach to frame-
work 1 and framework 4 regions. VHH genes were puriﬁed from
agarose (Bioneer, Korea) and cloned into an sﬁI digested pcomb3x
phagemid vector. Recombinant phagemids were transformed into
XL1-Blue Escherichia coli electrocompetent cells. The transformed
bacteria were then sub-cultured on Luria-Bertani (LB)–ampicillin
(80 mg/ml) agar plates.
2.5. Panning of the VHH library
VHH fragments were displayed on a phage after infecting the
host bacteria with M13K07 helper phage (Amersham-Pharmacia-
Biotech, Vienna, Austria). Brieﬂy, a phage library was grown in
300 ml of SB (Super Broth) medium containing 80 mg/ml ampicil-
lin. Bacteria at mid-log phase at OD600 of 0.5–0.7 were infected
with 3 ml of M13K07 helper phage with 1011 pfu/ml. Infected
bacteria were incubated stationary for 30 min and then with
shaking for 30 min at 37 8C. Kanamycin 70 mg/ml was added to the
culture and incubated at 37 8C for 16 h with shaking at 250 rpm.
The culture was centrifuged for 20 min at 4000  g at 4 8C. PEG
6000 (20%) and 2.5 M NaCl was added to the supernatant and this
was incubated for 60 min on ice. After centrifugation for 15 min at
15 000  g at 4 8C the pellet was resuspended in 2–3 ml of 1%
bovine serum albumin (BSA). The suspension was centrifuged for
5 min at 12 000  g and phage-containing supernatant was
collected for biopanning.
Speciﬁc VHHs for UreC were propagated by ﬁve rounds of
biopanning. The microplate was coated overnight at 4 8C with UreC
recombinant protein with Tris-buffered saline (TBS). One hundred
microliters of concentrated phage library was added to the wells.
The washing intensity and frequency were increased throughout
the panning process with ascending amounts of Tween-20 in PBS-T
from 0.1% to 0.5%. The bound phages were eluted with glycine–HCl
0.2 M pH 2.2 and neutralized in 1 M Tris buffer pH 9. Half of the
eluted phages were used to infect E. coli XL1-Blue in the mid-log
phase and the other half were used for propagation and polyclonal
phage ELISA. Polyclonal phage ELISA was used to assess the
panning process. Colonies were randomly selected from the third
round of panning and screened for VHH gene by PCR. VHH afﬁnity
towards UreC protein in positive clones was assessed by phage
ELISA. UreC proteins, 10 mg/ml, were coated for 16 h at 4 8C in
microplate wells with TBS. The wells were blocked with 150 ml of
5% skim milk in PBS-T for 1 h and were then washed with PBS-T.
The puriﬁed phages from selected clones were then added to the
wells and incubated for 2 h at 37 8C. After washing with 200 ml of
PBS-T, 100 ml anti-M13 monoclonal antibody conjugated to HRP
(Amersham-Pharmacia-Biotech, Vienna, Austria) was added at a
ﬁnal concentration of 1/8000 and the microplate was incubated for
1 h at 37 8C. TMB substrate was added after washing and the
reaction was stopped with H2SO4 (3 N) after 15 min. Color
intensity was measured at 450 nm by ELISA reader.
2.6. Expression of VHH fragment
The C5 clone that scored the highest OD in monoclonal phage
ELISA was selected for expression of soluble periplasmic VHH and
was transformed into E. coli Top10F0. Expression was induced with
L.S. Ardekani et al. / International Journal of Infectious Diseases 17 (2013) e723–e728 e7251 mM isopropylthio-b-galactoside (IPTG; Bangalore GeNei, India)
at OD600 of 0.5 at 28 8C. Cell pellets were collected by centrifuga-
tion at 5000  g at 4 8C for 20 min. Pellets were sonicated in lysis
buffer containing PBS with protease inhibitor phenyl methyl
sulfonyl ﬂuoride at a ﬁnal concentration of 1.0 mM. After
centrifugation the supernatant was collected and production of
nanobody was analyzed by 14% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE).
2.7. Over-expression of nanobody
The selected nanobody was subcloned into pET28a expression
vector using a pair of PCR primers, Fr4-EcoR1 50-ACTTCAGAATTC-
GAGGTGCAGCTGSWGSAKTCKG-30 and Fr1-HindIII 50-ACTA-
CAAAGCTTTTAGGAGACGGTGACCWGGGTC-30, with EcoRI and
HindIII restriction sites.23 The construct was transformed into E.
coli BL21(DE3). VHH expression was then induced with 1 mM IPTG
for 16 h at 28 8C at OD600 of 0.5. Bacteria were harvested by
centrifugation at 4000  g at 4 8C for 10 min and then resuspended
in lysis buffer. The cells were sonicated on ice. After centrifugation,
the cleared supernatant was loaded onto a nickel–nitrilotriacetic
acid (Ni–NTA) agarose column (Qiagen, Valencia, CA, USA). The
bound proteins were eluted with 250 mM imidazole.
2.8. SDS-PAGE and Western blotting
The puriﬁed nanobody was studied on 14% SDS-PAGE under
reducing conditions. The gel was stained with Coomassie brilliant
blue. For Western blotting the gel was run at a constant voltage of
100 V for 45 min. The protein bands were then transferred to the
nitrocellulose membrane using a Mini Protein Tetra System (Bio-
Rad). The nitrocellulose membrane was blocked with 5% skim milk
in PBS-T for 16 h at 4 8C. The membrane was washed and detection
was done with 1/5000 dilution of HRP conjugated anti-His Tag
antibody (Abcam, UK) and diaminobenzidine (DAB) (Bangalore
GeNei, India) as substrate.
2.9. Sequencing
The VHH sequence of C5 clone was performed with VHH F and
VHH R primers and the result was compared with the NCBI
database.
2.10. Assessment of nanobody binding afﬁnity to UreC
Afﬁnity of the puriﬁed nanobody was determined using ELISA.
UreC at 1.25, 2.5, 5, and 10 mg/ml concentrations were coated in
microplate wells. After washing and blocking as described earlier,
the nanobody was added at 0, 1.25, 2.5, 5, and 10 mg/ml
concentrations. HRP-conjugated anti-His antibody was added and
the immune reactivity was developed with TMB substrate. The
reaction was stopped with 3 N H2SO4 and OD450 was measured.
38
2.11. Binding speciﬁcity
Various antigens produced and standardized in our biotechnology
laboratory such as UreC, H. pylori, recombinant C-terminal fragment
of UreC protein, BSA, Vibrio cholerae lipopolysaccharide, Salmonella
typhimurium lipopolysaccharide, Acinetobacter bioﬁlm-associated
protein, and Clostridium botulinum neurotoxin type E, were incubated
in microplate ELISA at 10 mg/ml concentrations for 16 h at 4 8C. ELISA
was performed as described in the section on ELISA.
2.12. Evaluation of nanobody inhibitory effect
H. pylori (109 cfu) was mixed with different concentrations of
nanobody and incubated in microplate wells for 16 h at 4 8C. Onehundred microliters PBS containing 500 mM urea and 0.2 g/l
phenol red was added to the wells and incubated for 3 h at 37 8C.
Three controls including the culture media, H. pylori, and nanobody
were used. Colorimetric measurement at OD550 was done every
30 min during a 3-h period. The inhibition percentage was
calculated as: inhibition percentage = [(the enzymatic activity of
bacteria without nanobody  the enzymatic activity of bacteria
with nanobody)/the enzymatic activity of bacteria without nano-
body]  100.12
2.13. In vitro proteolytic stability of VHHs
Proteolytic stability of VHHs was analyzed using porcine pepsin
and bovine trypsin. Puriﬁed nanobody, 5 and 10 mg/ml, was
incubated with different concentrations of pepsin in10 mM HCl
(pH 2) and trypsin in 1 mM Tris–Cl and 20 mM CaCl2 (pH 8. 0) for
1 h at 37 8C prior to the test. For the control test, PBS was used
instead of proteolytic enzymes. The afﬁnity of nanobody was
determined by antigen-speciﬁc ELISA as described in the section on
ELISA.
2.14. Temperature treatment
Nanobody, 5 and 10 mg/ml, in PBS was incubated for 2 h at
various temperatures (4 8C, 25 8C, 60 8C, 80 8C, and 90 8C), followed
by a 30-min incubation at room temperature (RT), and then stored
at 4 8C. The ELISA was developed as described in the section on
ELISA.
2.15. Binding in the presence of urea
Different concentrations of nanobody (5 and 10 mg/ml) were
incubated overnight at room temperature in 0–8 M urea in PBS.
The ELISA was carried out as mentioned earlier, using urea-treated
nanobodies.
3. Results
3.1. Camel immune response
Immune camel serum at 1/1000, 1/3000, and 1/10 000
dilutions, and non-immune camel serum as a negative control,
were assessed by indirect ELISA using UreC recombinant protein as
an antigen. The antibody titer of the immune serum against UreC
reached a maximum of about 0.7 after the ﬁfth injection, as against
0.1 of the normal serum.
3.2. Construction and panning of the nanobody library
Lymphocytes were isolated from anti-coagulated blood of an
immunized camel. Total RNA were puriﬁed from 106 cells
(Figure 1a). cDNA was prepared from puriﬁed RNA. The ampliﬁed
fragments are derived from classical antibody (900 bp) and heavy
chain antibody (700 600 bp). The regions between CH2 and
framework 1 were ampliﬁed (Figure 1b). In the second PCR, the
VHH fragments (400 bp) were generated with speciﬁc primers that
attach to framework 1 and framework 4 and amplify the variable
region (Figure 1c). The nanobody library was prepared with
3.2  107 members. Phages binding to UreC recombinant protein
were selected by ﬁve consecutive rounds of biopanning against
recombinant UreC. The third round of panning showed the highest
immunoactivity in the polyclonal phage ELISA (Figure 2).
In the monoclonal phage ELISA, 18 clones were screened from
the third round of panning that bound strongly to UreC
recombinant protein and showed minimal afﬁnity towards control
BSA. The C5 clone showing the highest OD was selected for further
Figure 1. Library construction. (a) Clear deﬁnition of the ribosomal RNA 28S and 18S demonstrates the integrity of the samples. (b) Analysis of the ﬁrst PCR product with
agarose gel electrophoresis (1%); lanes 1, 2, and 3: the PCR product with different sizes 900, 700, and 600 bp, respectively; lane 4: molecular weight marker. (c) Analysis of the
second PCR product by gel electrophoresis (1%); the VHH fragment with 400 bp size is marked.
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homology (92%) with the VHH sequence of Camelus dromedaries
in the NCBI database.
3.3. SDS-PAGE and Western blot
For production of soluble nanobody, the C5 phagemid was
transferred into non-suppressor E. coli Top10F0. The nanobody was
expressed with an OmpA leader signal for periplasmic secretion.
SDS-PAGE analysis showed an 18-kDa band (Figure 3a). For
characterization of nanobody, the anti-UreC-VHH gene was
subcloned into pET28a expression vector. Nanobody was
expressed in fusion with N-terminal His-tag and puriﬁed by
NTA-afﬁnity chromatography. The nanobody was eluted by an
imidazole buffer 250 mM (Figure 3b) and was conﬁrmed by
Western blotting. The puriﬁed nanobody showed an 18-kDa band
(Figure 3c).
3.4. Nanobody afﬁnity determination
Afﬁnity of the puriﬁed nanobody measured by ELISA was
5  108 M.
3.5. Cross-reactivity of the nanobody
The nanobody was speciﬁc for UreC and no cross-reactivity was
observed with BSA, V. cholerae lipopolysaccharide, S. typhimurium
lipopolysaccharide, Acinetobacter bioﬁlm-associated protein, or C.
botulinum neurotoxin type E.Figure 2. Assessment of the panning process with phage ELISA. The absorbance and
enrichment against UreC was increased and the highest enrichment was obtained
in the third panning. The absorbance against BSA (negative control) remained
constant.3.6. Urease inhibitory effect
A serial dilution of nanobody (from 0 to 100 mg/ml) incubated
with H. pylori showed elevated urease inhibition with the
increasing concentration of the nanobody. The minimum amount
of nanobody required to inhibit urease activity was calculated as
70 mg/ml and the maximum urease inhibition was calculated as
35% (Figure 4).
3.7. Proteolytic stability
The nanobodies retained their full activity even when incubated
with 1 mg of proteolytic enzymes.
3.8. Temperature stability
Nanobodies preserved functional activity even after incubation
at 90 8C. The results demonstrate that antigen binding in
nanobodies is unaffected by the temperature.
3.9. Binding in the presence of urea
Nanobody had preserved binding when tested in an ELISA
experiment in the presence of increasing amounts of Urea. This
result suggests that the urea-treated VHHs retained function and
antigen binding ability even in denaturing conditions.
4. Discussion
The prevalence of antibiotic-resistant H. pylori strains, the high
cost of treatment, and the risk of relapse, have led to the need for a
new approach to the treatment of H. pylori-related diseases.11 The
effects of various inhibitors such as L-ascorbic acid, copper ions,
and acetohydroxamic acid on H. pylori urease activity have been
investigated in previous studies. However, the use of such
compounds in vivo causes problems such as toxicity and
instability.13 So far, several monoclonal and single chain variable
fragment (scFv) antibodies against urease enzyme have been
produced.28–32 Due to problems such as low stability and low yield
of production and immunogenicity, the need for a new generation
of antibodies seems necessary.19
The variable domain of camel heavy chain antibody has
phenomenal features such as a small size and high stability and
afﬁnity, which makes it suitable for biotechnological applica-
tions.22,24–27 Because of the problems mentioned above, our aim
was to produce a phage displayed VHH library against UreC
recombinant protein and to screen for a nanobody with high
afﬁnity and speciﬁcity. In this study UreC was successfully
Figure 3. SDS-PAGE and Western blotting. (a) SDS-PAGE gel stained with Coomassie blue; lane M: molecular weight marker; lane 1: the expressed VHH after 1 mM IPTG
induction; lane 2: cell lysate before induction. (b) SDS-PAGE analysis of nanobody puriﬁed by Immobilized metal afﬁnity chromatography (IMAC); lane 1: molecular weight
marker; lanes 2–4: the fractions after washing with 20, 50, and 100 mM imidazole, respectively; lanes 5 and 6: the nanobody eluted by 250 mM imidazole buffer. (c) Western
blot analysis of VHH binding to UreC; lane M: molecular weight marker; lanes 1 and 2: the speciﬁc reaction of the HRP-conjugated anti-His Tag antibody with nanobody after
induction; lane 3: before induction.
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by ELISA was achieved after three booster injections. The 3.2  107
member nanobody phage library constructed in this work
indicates its adequate variety.
Urease is an important pathogenic factor that helps H. pylori
colonize the epithelium in the acidic environment of the
stomach.29 This enzyme exists in two forms of cytoplasmic and
surface protein and releases NH3 by hydrolyzing urea.
14 The urease
enzyme was selected for its unique role in H. pylori colonization
and survival.
To date, many VHH phage libraries have been reported. In these
publications the afﬁnities of selected antibodies have been
calculated to be in the range of 109 to 1010.39,40 The afﬁnity
of monoclonal antibody and scFv fragments against urease has
ranged from 1.7  108 to 3  109.28,30,31 In the present work the
afﬁnity of nanobody against UreC recombinant protein was
5  108 M. This is high in comparison with the previous reports.
VHHs, unlike conventional antibodies, can recognize epitopes such
as cavity and cleft in the active sites as they have a convex
paratope.27 Our nanobody has advantages over those of previous
studies in this respect. Furthermore the VHH stability tests
revealed high thermostability and resistance to denaturing agents
and proteolytic enzymes. The resistance to proteolytic enzymes is
of signiﬁcant importance in the oral administration of anti-H. pylori
antibodies. This characteristic allows the oral administration of
VHH in the treatment of stomach ulcer without any loss of binding
activity. Resistance to thermal denaturation and the retention of
full activity after incubation at high temperatures increases the
antibody’s shelf-life. The results of the urease inhibitory test
showed that nanobody can successfully inhibit the surface urease
activity of H. pylori. This can signiﬁcantly reduce bacterial survival
in acidic environments such as the stomach.
The results suggest that single domain antibodies with high
afﬁnity and speciﬁcity could be a novel class of treatment measure
in H. pylori infection. Implementing our previous successful in vivoFigure 4. Neutralization of Helicobacter pylori urease activity by the nanobody. H.
pylori was treated with nanobody and the optical density of the mixture was
determined at 550 nm by phenol red indicator showing 35% inhibition.study15 to the present work would add practical dimensions to our
ﬁndings.
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